Literature DB >> 10515809

Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats.

D H Gebhard1, J L Dow, T A Childers, J I Alvelo, M B Tompkins, W A Tompkins.   

Abstract

The acute stage of feline immunodeficiency virus (FIV) infection is characterized by the appearance of a major CD8 subpopulation with reduced expression of the CD8 beta chain (CD8alpha+betalo). CD8 antiviral activity was subsequently shown to be mediated by the CD8alpha+betalo phenotype, which is the dominant CD8 phenotype in long-term infected cats. Two- and three-color flow cytometric analysis demonstrated that the CD8alpha+betalo subset is L-selectin negative (CD62L-) and has increased expression of CD44, CD49d, and CD18, consistent with an activation phenotype. The CD8alpha+betaloCD62L- cells but not the CD8alpha+betahiCD62L+ cells demonstrated strong antiviral activity in the FIV acute-infection assay. The progressive expansion of the CD8alpha+betaloCD62L- effector subset cells in FIV-infected cats parallels that seen in human immunodeficiency virus (HIV)-infected patients, suggesting that failure in homeostatic mechanisms regulating lymphocyte activation or trafficking (or both) may be a consequence of both HIV and FIV infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515809     DOI: 10.1086/315089

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells.

Authors:  M Scott Killian; Carl Johnson; Fernando Teque; Sue Fujimura; Jay A Levy
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

Review 3.  The neuropathogenesis of feline immunodeficiency virus infection: barriers to overcome.

Authors:  Nicola F Fletcher; Rick B Meeker; Lola C Hudson; John J Callanan
Journal:  Vet J       Date:  2010-04-24       Impact factor: 2.688

Review 4.  Lentivirus-induced immune dysregulation.

Authors:  Mary B Tompkins; Wayne A Tompkins
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

5.  Prior mucosal exposure to heterologous cells alters the pathogenesis of cell-associated mucosal feline immunodeficiency virus challenge.

Authors:  Surender B Kumar; Sarah Leavell; Kyle Porter; Barnabe D Assogba; Mary J Burkhard
Journal:  Retrovirology       Date:  2010-05-28       Impact factor: 4.602

Review 6.  Immunopathogenesis of feline immunodeficiency virus infection in the fetal and neonatal cat.

Authors:  Holly M Kolenda-Roberts; Leah A Kuhnt; Ryan N Jennings; Ayalew Mergia; Nazareth Gengozian; Calvin M Johnson
Journal:  Front Biosci       Date:  2007-05-01

7.  CD8+ clonality is associated with prolonged acute plasma viremia and altered mRNA cytokine profiles during the course of feline immunodeficiency virus infection.

Authors:  Michelle M Miller; Elizabeth M Thompson; Steven E Suter; Jonathan E Fogle
Journal:  Vet Immunol Immunopathol       Date:  2012-12-20       Impact factor: 2.046

8.  Loss of naïve (CD45RA+) CD4+ lymphocytes during pediatric infection with feline immunodeficiency virus.

Authors:  Abigail D Carreño; Ayalew Mergia; Janelle Novak; Nazareth Gengozian; Calvin M Johnson
Journal:  Vet Immunol Immunopathol       Date:  2007-09-11       Impact factor: 2.046

Review 9.  Feline immunodeficiency virus neuropathogenesis: from cats to calcium.

Authors:  Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2006-11-28       Impact factor: 4.147

10.  Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems.

Authors:  Kristina E Howard; Mary Jo Burkhard
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.